Juno enters MM deal with MSKCC, Eureka

Memorial Sloan Kettering Cancer Center and Eureka Therapeutics Inc. (Emeryville, Calif.) granted Juno Therapeutics Inc. (NASDAQ:JUNO) exclusive, worldwide rights to binding domains against three multiple myeloma (MM) targets. Juno will incorporate the targets into chimeric antigen receptor (CAR) T cell therapies to treat MM.

The deal includes a binding domain targeting tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA; TNFRSF17; CD269). Juno said its CAR T therapy against BCMA could enter the clinic as early as 1H17. The deal's other two targets are undisclosed. MSKCC and Eureka are eligible for an undisclosed upfront payment and milestones, plus royalties. ...